SILREAL at BIO-Europe 2026
Nov 9–11, 2026 Cologne, Germany ~5.8k attendees Website
SILREAL takes part in 2 sessions at BIO-Europe 2026 in Cologne. Its sessions centre on China's rise in clinical development and what it means for deals. One sets out what Western buyers must resolve about China-origin evidence and policy risk before they sign.
| Organization | BIO-Europe 2026 Attendance |
|---|---|
Consultancy advising pharma, medtech and digital health companies on China-Europe policy, regulation, market access and expansion. | Talk Tue Nov 10 09:30–09:45 Before the Deal: What Western Buyers Must Resolve About China-Origin Evidence and Policy Risk What Western buyers should check before buying rights to a China-developed drug, from whether its trial data satisfy European regulators to political risk. Panel Tue Nov 10 09:45–10:45 China’s Clinical Revolution: From Regional Player to Global Innovation Engine Why global drug companies license more drugs from Chinese biotechs, and how China's fast trials and changing rules can speed worldwide development. |
Instantly find 20 buyers from SILREAL
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by EBD Group, Informa Connect or BIO-Europe. Submit a correction